Adriana santagati
08/26/2020 - 16:21
- Clarín.com
- Society
A third vaccine against the coronavirus will be tested in Argentina. It is that of the Belgian laboratory Janssen , which is part of the Johnson & Johnson group. Thus, there will be three clinical trials to be developed in the country.
As Clarín had anticipated, Argentina was one of the points of interest for Janssen, and had already presented the protocol in the National Administration of Medicines and Medical Technology (ANMAT). Now, the pharmaceutical company confirmed that it will be one of the eight countries where the phase 3 trial will take place.
The study is scheduled to start in September , the company announced in a statement, clarifying that this is subject to the approval of health authorities and also to the results of the Phase 1 / 2a study.
The research will involve a total of 60,000 volunteers aged 18 and over. In addition to Argentina, South Africa, the United States, Brazil, Chile, Colombia, Mexico and Peru will participate. It was not reported how many participants will be Argentines or which center will coordinate the research.
"Data from epidemiological models have been used to project and plan where these studies should take place. The final selection of these countries was determined in close collaboration with local governments and health authorities. The current prevalence of the disease, the demographics of the population and the requirements of the health authorities , in order to ensure that the study can be carried out properly and provide relevant data. "
News in development